Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893453 | 0.79 | SRC (0.52) | PRKCQPRKCD | |
| SCHEMBL4947269 | 0.76 | CSNK2A2 (0.45) | MAPTHPGDALDH1A1NPC1HSD17B10 | |
| SCHEMBL4947800 | 0.71 | SLC22A12 (0.40) | MAPTALDH1A1SMN1; SMN2SLC22A12KDM4E | |
| SCHEMBL4892667 | 0.70 | HPGD (0.36) | MAPTHPGDALDH1A1TSHRNPC1 | |
| SCHEMBL21708099 | 0.70 | MEN1 (0.43) | KMT2A | |
| SCHEMBL3992555 | 0.69 | CSNK1A1 (0.34) | PRKCQPRKCDALDH1A1KMT2A | |
| SCHEMBL3995602 | 0.69 | ADORA1 (0.45) | PRKCQALDH1A1 | |
| SCHEMBL4947940 | 0.68 | CSNK1A1 (0.36) | PRKCQPRKCDALDH1A1CYP11B2 | |
| SCHEMBL3996010 | 0.66 | CYP2A6 (0.35) | PRKCQPRKCDALDH1A1RAB9A | |
| SCHEMBL3993667 | 0.66 | CSNK1A1 (0.34) | PRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-6987116-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2006-01-17 | — | — | US | disclosed |
| EP-1565474-A2 | THIENO[3,2-B]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048386-A9 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-12-02 | — | — | US | disclosed |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004048386-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | PRKCQ 79/4885PRKCD 124/4885MAPT 3856/4885 |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, PTK2B, PKN1 | PRKCQ 100/4885PRKCD 134/4885MAPT 3782/4885 |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PTK2B, PKD1, PKN1 | PRKCQ 599/4885PRKCD 422/4885MAPT 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.